Abstract
Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause. MHT, initiated in women during the “therapeutic window” to relieve symptoms of estrogens deficiency and prevent or treat osteoporosis, is the only intervention that reduces the risk of cardiovascular diseases and diabetes in healthy middle-aged women. MHT must be individualized and adapted; that is, a differentiated selection of therapy should be carried out, considering the woman’s health status and her comorbidities, as well as the MHT regimen (type, dose, route of administration and possible side effects). The article reflects the algorithms for prescribing MHT in different periods of menopause, which allow applying an individualized approach to patients who need MHT.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
